Corcept Therapeutics (CORT) Competitors $69.31 -4.09 (-5.57%) Closing price 04:00 PM EasternExtended Trading$70.14 +0.83 (+1.19%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CORT vs. RPRX, JAZZ, PRGO, SUPN, PCRX, OMER, ASMB, NKTR, CPIX, and LLYShould you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Omeros (OMER), Assembly Biosciences (ASMB), Nektar Therapeutics (NKTR), Cumberland Pharmaceuticals (CPIX), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceuticals" industry. Corcept Therapeutics vs. Its Competitors Royalty Pharma Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Pacira BioSciences Omeros Assembly Biosciences Nektar Therapeutics Cumberland Pharmaceuticals Eli Lilly and Company Royalty Pharma (NASDAQ:RPRX) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability. Which has more volatility and risk, RPRX or CORT? Royalty Pharma has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Is RPRX or CORT more profitable? Royalty Pharma has a net margin of 48.23% compared to Corcept Therapeutics' net margin of 19.33%. Royalty Pharma's return on equity of 24.71% beat Corcept Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Royalty Pharma48.23% 24.71% 13.87% Corcept Therapeutics 19.33%20.40%16.64% Do analysts prefer RPRX or CORT? Royalty Pharma presently has a consensus target price of $47.33, suggesting a potential upside of 32.25%. Corcept Therapeutics has a consensus target price of $138.25, suggesting a potential upside of 96.42%. Given Corcept Therapeutics' higher probable upside, analysts clearly believe Corcept Therapeutics is more favorable than Royalty Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Royalty Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation & earnings, RPRX or CORT? Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoyalty Pharma$2.26B8.89$858.98M$1.8519.35Corcept Therapeutics$675.04M11.06$141.21M$1.1660.68 Does the media prefer RPRX or CORT? In the previous week, Royalty Pharma had 6 more articles in the media than Corcept Therapeutics. MarketBeat recorded 20 mentions for Royalty Pharma and 14 mentions for Corcept Therapeutics. Royalty Pharma's average media sentiment score of 1.05 beat Corcept Therapeutics' score of 0.99 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 10 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in RPRX or CORT? 54.3% of Royalty Pharma shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 18.9% of Royalty Pharma shares are owned by insiders. Comparatively, 20.5% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryRoyalty Pharma beats Corcept Therapeutics on 10 of the 17 factors compared between the two stocks. Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CORT vs. The Competition Export to ExcelMetricCorcept TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.43B$2.42B$5.52B$8.87BDividend YieldN/A1.80%5.36%4.13%P/E Ratio60.409.1126.4319.81Price / Sales11.06644.17409.77110.94Price / Cash58.9521.1625.8827.49Price / Book10.844.487.945.38Net Income$141.21M$31.16M$3.15B$248.34M7 Day Performance-8.34%1.06%1.15%1.43%1 Month Performance-9.89%10.86%5.48%5.61%1 Year Performance115.40%1.82%33.02%18.27% Corcept Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CORTCorcept Therapeutics4.7111 of 5 stars$69.31-5.6%$138.25+99.5%+125.9%$7.35B$675.04M59.75300RPRXRoyalty Pharma4.9118 of 5 stars$35.40+1.5%$47.33+33.7%+36.6%$19.90B$2.26B19.1480Positive NewsAnalyst DowngradeJAZZJazz Pharmaceuticals4.9029 of 5 stars$106.76-0.7%$184.00+72.3%-0.6%$6.46B$4.07B14.232,800PRGOPerrigo4.8418 of 5 stars$26.43-0.3%$33.00+24.9%+4.1%$3.63B$4.34B-20.188,379SUPNSupernus Pharmaceuticals2.3309 of 5 stars$31.99-0.9%$36.00+12.5%+17.8%$1.79B$661.82M28.82580PCRXPacira BioSciences3.509 of 5 stars$24.74+2.1%$26.44+6.9%-16.5%$1.15B$700.97M-10.85720OMEROmeros3.6825 of 5 stars$3.19-0.6%$18.00+464.3%-26.1%$186.90MN/A-1.20210Analyst ForecastASMBAssembly Biosciences3.6222 of 5 stars$17.10-1.7%$33.00+93.0%+32.1%$130.64M$28.52M-2.74100Trending NewsHigh Trading VolumeNKTRNektar Therapeutics4.6171 of 5 stars$9.54+12.1%$67.50+607.5%+38.9%$118.39M$98.43M-0.99220Gap DownHigh Trading VolumeCPIXCumberland Pharmaceuticals0.5514 of 5 stars$3.93-9.7%N/A+119.0%$58.79M$37.87M-15.7280Trending NewsLLYEli Lilly and Company4.986 of 5 stars$770.16+1.0%$1,011.79+31.4%-13.9%$729.91B$45.04B62.6747,000Positive NewsAnalyst Downgrade Related Companies and Tools Related Companies Royalty Pharma Competitors Jazz Pharmaceuticals Competitors Perrigo Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Omeros Competitors Assembly Biosciences Competitors Nektar Therapeutics Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CORT) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
